Iron a tiny molecule with huge effects. Our findings showed that iron participates in drug resistance and iron‐overload can be considered as a risk factor for relapse. In an attempt to minimize the probability of drug resistance and improve the treatment outcomes in children with ALL, it is suggested that patients' bone marrow iron stores must be assessed during chemotherapy, and the number of blood transfusions should be carefully monitored. Abstract Drug resistance is a fundamental clinical concern...
12h
Our study findings show that melanoma patients have a 24% higher risk of developing prostate cancer. This could be attributed to various environmental, hormonal and genetic factors. Early diagnosis of prostate cancer in melanoma patients may help in risk stratification. Abstract Background The risk of prostate cancer in melanoma patients has been frequently assessed. However, a comprehensive meta‐analysis specifically examining this association is lacking. Our aim was to quantify the risk of...
12h
This research inferred potential aberrantly methylated DEGs and dysregulated pathways may participate in EC development and firstly reported 8 hub genes, including EDNRB, CDO1, NDN, PLCD1, ROR2, ESPL1, PRAME and PTTG1 that could be used to predict EC prognosis. Aminoglutethimide and luteolin may be used to fight against EC. Abstract Endometrial cancer (EC) is a fatal female reproductive tumor. Bioinformatic tools are increasingly developed to screen out molecular targets related to EC. In this...
12h
A randomized phase 3 trial compared palonosetron with granisetron as combination therapy with dexamethasone and fosaprepitant for chemotherapy‐induced nausea and vomiting prevention in breast cancer patients receiving anthracycline and cyclophosphamide. Although palonosetron was better than granisetron in terms of control of nausea in the delayed phase, the primary endpoint, CR in the delayed phase, was not statistically significant (62.3% vs 60.4%). Abstract Purpose To investigate whether palonosetron...
12h
For first‐line treatment in advanced NSCLC with ROS1 rearrangement, crizotinib is more beneficial than platinum‐based chemotherapy. Patients harboring ROS1 CD74 fusion variants who are treated with first‐line crizotinib therapy have better PFS than those harboring non‐CD74 fusion variants. With first‐line platinum‐based chemotherapy, patients in both the CD74 and non‐CD74 fusion variant groups demonstrated a short PFS with no significant difference observed. Abstract Background ROS1 gene fusion...
12h
Our data indicated that 5‐FU was the key drug for treatment and OHP alone had the additional effect in combination with 5‐FU. Abstract Basic and clinical studies on small bowel adenocarcinoma (SBA) are limited due to the rare nature of this cancer. We established a patient‐derived xenograft (PDX) model from the tumor tissue of an advanced SBA patient with liver and peritoneal metastasis, and a cell line from the PDX. In the PDX model, compared to the control group, 5‐fluorouracil (5‐FU) treatment...
12h
Delayed presentation to medical care is common in male breast cancers, resulting in late presentation and poor prognosis. Reasons for the delayed presentation include lack of awareness of male breast cancer and embarrassment to feminine symptoms. Abstract Introduction Male breast cancer is uncommon, delay in seeking medical attention often results in late presentation and poor prognosis. Methods Retrospective review of a prospectively maintained database was performed. Patients who were...
12h
This is the first study to compare crizotinib with chemotherapy in ROS1+NSCLC. Crizotinib was superior to platinum‐pemetrexed chemotherapy as an initial treatment. Abstract Objectives Food and Drug Administration (FDA) approved crizotinib for advanced ROS1‐rearranged (ROS1+) non‐small‐cell lung cancer (NSCLC) patients due to a single‐arm study PROFILE 1001. However, there is no direct comparison between crizotinib and platinum‐pemetrexed chemotherapy. Materials and methods Clinical data...
12h
Our study confirmed that circ‐PGAM1 promoted proliferation, migration, and invasion and inhibited apoptosis of ovarian cancer cells through down‐regulation of miR‐542‐3p. MiR‐542‐3p played a tumor‐suppressing role through down‐regulation of CDC5L. CDC5L was a downstream target of miR‐542‐3p, and PEAK1 is a downstream target of CDC5L. Abstract Background Epithelial ovarian cancer (EOC) is the most common ovarian malignant cancer. Circular RNA is a type of endogenous noncoding RNA and is considered...
12h
The number of opioid prescriptions written by radiation oncologists are related to specific physician and practice characteristics; further investigation is needed to establish opioid prescribing best practices within radiation oncology. Abstract Background Radiation oncologists (ROs) play an important role in managing cancer pain; however, their opioid prescribing patterns remain poorly described. Methods The 2016 Medicare Physician Compare National Downloadable and the 2016 Medicare...
12h
12h
We found it very accurate to evaluate the effect of abiraterone on prostate cancer using PSMA molecular imaging. PSMA imaging is expected to replace traditional imaging in prostate diagnosis and treatment Abstract To investigate the feasibility and effectiveness of prostate‐specific membrane antigen (PSMA) imaging to make response assessment regarding novel hormone treatment and to predict the outcomes for metastatic castration‐resistant prostate cancer (mCRPC) patients. This retrospective study...
12h
Kaplan‐Meier curves for TD negative and positive gastric patients before and after propensity score matching. Abstract Background Gastric cancer (GC) treatment is determined by accurate tumor staging. The value of tumor deposit (TD) in prognostic prediction staging system is not yet determined. Methods We retrospectively analyzed clinical information on GC patients who underwent gastrectomy at the Department of General Surgery of the Chinese PLA General Hospital from July 2014 to June...
12h
Expert groups published recommendations regarding clinically meaningful outcomes for single‐arm trials evaluating the efficacy of novel therapies in BCG‐unresponsive non‐muscle invasive bladder cancer. In this study, we used a discrete event simulation framework in combination with a supercomputer to demonstrate that these recommendations do probably not reflect clinically meaningful outcomes and should be increased to at least 45%‐55% at 6 months and 35% at 18‐24 months (complete response rates/recurrence‐free...
12h
This study identifies ASCT2 is a significant prognostic factor for predicting overall survival of OSCC patients. Targeted ASCT2 knockdown effectively inhibits cancer growth in vitro and in vivo via inhibiting GSH synthesis and inducing ROS‐mediated apoptosis. Targeting ASCT2 may provide a novel strategy for OSCC treatment. Abstract Background Alanine‐serine‐cysteine transporter 2 (ASCT2), a major glutamine transporter, is essential for cell growth and tumor development in a variety of...
12h
We found that Sp2 expression was significantly up‐regulated in HCC tissues, which was closely related to tumor staging and poor prognosis of patients. Functional studies had shown that Sp2 knockdown not only leads to a decrease in cell proliferation and an increase in cell apoptosis, but also inhibits migration and invasion of hepatoma cells. Sp2 may play a role in promoting cancer by regulating TRIB3 protein, which may be a prognostic factor and a potential new therapeutic target for HCC. Abstract...
12h
Dose per fraction and overall treatment time can impact tolerance of prostate SBRT. Urethra‐sparing SBRT showed a low toxicity profile and minimal impact on QoL. An EOD or QW SBRT schedule had a comparable tolerance and efficacy at 18 months. Abstract Background To present the 18 months results from a prospective multicenter phase II randomized trial of short vs protracted urethra‐sparing stereotactic body radiotherapy (SBRT) for localized prostate cancer (PCa). Methods Between...
12h
In an urban hospital, >90% of patients achieve diagnostic resolution after uncertain screening mammogram. Chinese patients without an integrated primary care provider (PCP) are at risk of less timely diagnostic resolution than Chinese patients with integrated PCP. Abstract Background Screening mammography has reduced breast cancer–associated mortality worldwide. Approximately 10% of patients require further diagnostic testing after an uncertain screening mammogram (Breast imaging reporting...
12h
Our study included 477 Burkitt Lymphoma (BL) patients with gastrointestinal involvement extracted from the SEER database between 2004 and 2015, 112 (23.5%) with the stomach and 365 (76.5%) with the intestine. We demonstrated that BL patients with gastric involvement had an inferior prognosis compared to those with intestinal involvement (5‐year OS 37.8% vs. 70.2%). In subgroup analysis, gastric BL patients had a consistently worse OS than intestinal patients regardless of gender, clinical stage and...
12h
A survey of over 1200 physicians working at accredited breast centers in the United States showed there is consensus among physicians on the most appropriate indication for contralateral prophylactic mastectomy (CPM) but opinions vary on CPM as a quality measure and insurance coverage for CPM. Abstract Background Indications and insurance coverage for contralateral prophylactic mastectomy (CPM) and CPM as a quality measure are controversial. Few studies have examined physician opinions on these...
12h
The cover image is based on the Original Research Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era by Michael E. Roth et al., https://doi.org/10.1002/cam4.2891. Cover image © Wiley Images.
12h
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου